<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653261</url>
  </required_header>
  <id_info>
    <org_study_id>University Tunis El Manar</org_study_id>
    <nct_id>NCT02653261</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology</brief_title>
  <official_title>Safety and Efficacy of Intravenous Tranexamic Acid in Reducing Blood Transfusion After Endoscopic Transurethral Resections in Urology: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Tunis El Manar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Tunis El Manar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transurethral resection of the prostate (TURP) represents the gold standard in the operative&#xD;
      management of benign prostatic hyperplasia (BPH) and the transurethral resection of bladder&#xD;
      tumor (TURBT) is the first-line surgical treatment for bladder tumors. One of the most&#xD;
      important complications of urological endoscopic resections is intraoperative and&#xD;
      postoperative bleeding requiring blood transfusion. Allogeneic blood transfusion is not free&#xD;
      of risks, like infection transmission, hemolytic reactions, transfusion-related lung injury,&#xD;
      fluid overload, increased costs and hospital length of stay.&#xD;
&#xD;
      Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by&#xD;
      blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA has been&#xD;
      used to reduce blood loss and the need for allogeneic blood transfusion in cardiac surgery&#xD;
      and orthopedic surgical procedures but few studies have assessed the efficacy of this&#xD;
      antifibrinolytic agent in urological endoscopic procedures.&#xD;
&#xD;
      The investigators designed this double-blind, placebo controlled study evaluate the safety&#xD;
      and efficacy of the antifibrinolytic agent tranexamic acid in reducing blood transfusion in&#xD;
      patients undergoing endoscopic surgery in urology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized into one of two study groups: Group TXA: intravenous&#xD;
      tranexamic acid: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1&#xD;
      mg/kg/h intraoperatively and for 24 h postoperatively. Control Group C: an equal volume of&#xD;
      saline. The study drug was prepared by an anesthesiologist not involved in the patient&#xD;
      management and data collection. The anesthetic technique will be standardized. Serum&#xD;
      hemoglobin was measured before and after surgery. The volume of the irrigation fluid,&#xD;
      resected prostate weight and duration of resection were recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of red blood cell transfusions</measure>
    <time_frame>From surgery until 72 hours postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference in preoperative and postoperative hematocrit levels to estimate blood loss.</measure>
    <time_frame>the first postoperative day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of acute urinary retention</measure>
    <time_frame>the first postoperative day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative bleeding with clot retention</measure>
    <time_frame>the first postoperative day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of bladder tamponade requiring evacuation or reintervention</measure>
    <time_frame>the first postoperative day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative myocardial ischemia assessed by cardiac troponin I</measure>
    <time_frame>the first postoperative day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic Acid (TXA): bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An equal volume of saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <other_name>Exacyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An equal volume of saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult (&gt;/=18)&#xD;
&#xD;
          2. male or female&#xD;
&#xD;
          3. Undergoing elective TURP or TURBT&#xD;
&#xD;
          4. Spinal anesthesia&#xD;
&#xD;
          5. Subject is American Society of Anesthesiologists (ASA) physical status 1 or 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Atrial fibrillation&#xD;
&#xD;
          2. Coronary artery disease treated with drug eluting stent&#xD;
&#xD;
          3. Severe chronic renal failure&#xD;
&#xD;
          4. Congenital or acquired thrombophilia&#xD;
&#xD;
          5. Known or suspected allergy to tranexamic acid.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali JENDOUBI</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Tunis El Manar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ali JENDOUBI</name>
      <address>
        <city>Tunis</city>
        <zip>1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>January 3, 2016</study_first_submitted>
  <study_first_submitted_qc>January 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <last_update_submitted>October 9, 2016</last_update_submitted>
  <last_update_submitted_qc>October 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Tunis El Manar</investigator_affiliation>
    <investigator_full_name>Ali JENDOUBI</investigator_full_name>
    <investigator_title>MD, Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>Transurethral Resection of the Prostate (TURP)</keyword>
  <keyword>Transurethral Resection of a Bladder Tumor (TURBT)</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Blood Transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

